Healthcare
Luye Pharma Group Ltd.(LYPHF)
Live Price
Offline$0.2041
+0.00% today
1Y Change
-23.84%
Window
Jun 25, 2025 โ Jun 16, 2026
- Market Cap
- $8.94B
- Revenue Growth
- +1.4%
- EPS Growth
- +757.1%
- Dividend Yield
- 0.0%
Coverage: 251 bars ยท Jun 25, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Luye Pharma Group Ltd. (LYPHF) is a Healthcare stock with a market cap of $8.94B and listed on OTC. The stock last traded around $0.20 and down 23.8% across the available one-year price window (Jun 25, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of +1.4%, EPS growth of +757.1%, a dividend yield of 0.0%. What stands out right now is revenue +1.4%, EPS +757.1%, free cash flow 0.0% with operating margin 19.6% and ROIC 3.1%. Valuation is more restrained than many high-expectation growth names at P/E 14.8 and price/sales 1.4. Stock Foundry combines LYPHF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+1.4% vs +7.6% peer median
Operating Margin
Near sector median
+19.6% vs +19.4% peer median
P/E
Below sector median
14.8 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report was closer to in-line
2026 was reported on Mar 29, 2026 with revenue below estimates by -9.5%.
The operating story is still moving forward
Revenue is running at +1.4% and EPS at +757.1%, with operating margin around 19.6%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 27, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 29, 2026 | +0.0% | +0.0% | +0.0% | +0.0% |
2025 Aug 28, 2025 | +18.8% | +0.0% | +0.0% | +0.0% |
2025 Mar 27, 2025 | -79.7% | +0.0% | +0.0% | +0.0% |
Benchmark Edge
LYPHF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
LYPHF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
LYPHF Max Drawdown
-48.33%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for LYPHF and SPY.
Company Overview
Luye Pharma Group Ltd.
Other OTC
Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Rivastigmine Transdermal Patch for the treatment of Alzheimer's disease; Fentanyl Transdermal Patch for cancer pain; Buprenorphine Transdermal Patch for chronic pain; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders, In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; Tiandixin used as an adjuvant therapy for malignant tumors, hydrothorax and ascites, and respiratory infections; Yitaida for acute promyelocytic leukemia and liver cancer; Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation; and Beitangning, a pioglitazone hydrochloride capsule to control blood glucose. Further, it offers Nuosen for acute upper digestive tract hemorrhage; Sailimai for the treatment of diarrhea; Apleek Transdermal Patch for contraception; Sidinuo for osteoporosis; Glucosamine hydrochloride tablets for osteoarthritis; Oulai, a compound sodium aescinate gel for local swelling; Oukai for the treatment of soft tissue swelling and venous edema; and Fengshiye for patients who have pains in bones, joints, and limbs. The company distributes and sells pharmaceutical drugs; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.
- Leadership
- Dian Bo Liu
- IPO Date
- Feb 18, 2021
- Employees
- 5.2k
- Street Address
- No. 15 Chuang Ye Road
- Mailing
- Yantai, 264003
- Region
- Yantai, CN
- Reporting Currency
- USD
- Investor Line
- +86 535 671 7618
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 14.8
- EV/EBITDA
- 7.3
- Price/Sales
- 1.4
- Price/Book
- 0.6
Growth
- Revenue
- +1.4%
- EPS
- +757.1%
- Free Cash Flow
- 0.0%
Profitability
- Gross Margin
- 66.0%
- Operating Margin
- 19.6%
- Net Margin
- 9.8%
- ROE
- 4.0%
- ROIC
- 3.1%
Balance Sheet
- Debt/Equity
- 0.59
- Current Ratio
- 1.53
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.